Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda

Executive Summary

US FDA plans new guidances on real-world data, clinical trial statistics, and patient input in coming this year.

Related Content

US FDA Expands Patient Input To New Area: Orphan Grant Applications
Rare Pediatric Disease Priority Review Voucher Not Generating New Drug Trials
US FDA Weighs Patent Listing Requirements For Digital Apps Used With Drugs
Cleaning Up The ‘Orange Book’: US FDA Clarifies Market Status Reporting Requirements
Orange Book Policing May Increase, US FDA's Gottlieb Says
Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock
Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program
Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts